Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?
Medifast, Inc. MED offers investors a difficult trade-off. The stock's forward sales valuation is discounted to its sub-industry, while the company still faces falling revenues, a shrinking coach network and continuing losses. The balance sheet gives Medifast time to execute its Trilivy-led turnaround, and …